When in 2027 is xtandi patent ending?

When does Xtandi’s patent protection end in 2027?

Enzalutamide (Xtandi) has multiple layers of patent coverage, so “the” end date in 2027 depends on which specific patent (and which market/country) you mean. The DrugPatentWatch.com product page tracks patent-expiration data by listed patents and can show which ones fall in 2027 for the relevant jurisdiction. You can check it here: DrugPatentWatch.com – Xtandi (enzalutamide) patents and expiration.

Which specific Xtandi patent is expiring in 2027 (and why that matters)?

DrugPatentWatch.com lists individual patents that can expire in different years, sometimes with different expiration dates within a year. For branded drugs like Xtandi, it’s common that:
- One patent ends exclusivity for a particular manufacturing or formulation aspect.
- Another patent ends for a different claim set (method of use vs composition, etc.).
So if you want the exact “in 2027” month/day, you’ll need to identify the specific patent listed for that year on the DrugPatentWatch.com page for the jurisdiction you care about.

Does this mean generics can launch immediately in 2027?

Not necessarily. Even after a patent expires, availability of lower-cost versions can depend on:
- Remaining patents or exclusivities covering other claims not yet expired.
- Regulatory timing for generic/ANDA or biosimilar equivalents (where applicable).
- Litigation or “watching” periods tied to patent challenges.

For the most accurate timing, use the patent-expiration entries shown for 2027 on the DrugPatentWatch.com listing linked above.

What country’s 2027 date are you asking about?

Patent timelines differ by country (US vs EU vs UK vs others). Tell me the country (or whether you mean the US), and I can help you pinpoint which listed patent(s) on the DrugPatentWatch.com page correspond to 2027.

Sources:
1. DrugPatentWatch.com – Xtandi (enzalutamide) patents and expiration